(This measure has not been amended since it was introduced. The summary of that version is repeated here.)
Expresses the sense of the Senate that the Centers for Medicare & Medicaid Services should: (1) begin an immediate reconsideration of the final National Coverage Determination on the Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic Conditions (CAG-000383N); (2) consult with members of the clinical oncology community to determine appropriate revisions to it: and (3) implement such revisions as soon as feasible, and brief Congress in advance of announcing such changes.